Bradmer Announces Second Quarter Operational and Financial Results

TORONTO, ONTARIO--(Marketwire - July 30, 2012) - Bradmer Pharmaceuticals Inc. (TSX VENTURE:BMR.H) ("Bradmer" or the "Company") today announced its second quarter 2012 operational and financial results.

Operational Highlights

On December 21, 2011, Bradmer announced that it had entered into a letter of intent dated December 20, 2011 to complete a business combination with Epic Production Technologies International Inc. On June 12, 2012 the Company announced that Epic and Bradmer had agreed to terminate the letter of intent between the parties.

The directors and officers of Bradmer intend to seek out new opportunities considered to be in the best interests of Bradmer and its shareholders.

Financial Results

Amounts in US dollars, unless specified otherwise, and results prepared in accordance with International Financial Reporting Standards ("IFRS").

For the three months ended June 30, 2012, we recorded a net loss of $38,000 or $0.002 per common share based on the weighted average outstanding shares of 19,659,726 during the three month period, compared to net income of $37,000 or $0.002 per common share for the quarter ended June 30, 2011 based on the weighted average outstanding shares of 19,659,726. The recovery of expenses from P1 Energy is the reason for the net income of $37,000 in the second quarter of 2011.

Research and development expenses totaled $NIL in the three months ended June 30, 2012, compared to $7,000 in the second quarter of 2011 consisting primarily of legal fees of $6,000. These costs were incurred in connection with the termination of the Duke License Agreement.

General and administrative expenses were $47,000 in the three months ended June 30, 2012 compared to a recovery of expenses of $44,000 in the same quarter of the prior year. Major expenses in 2012 consisted of consulting fees of $18,000, insurance premiums of $14,000 and audit fees of $6,000. In 2011, legal fees amounted to $92,000, of which $70,000 was incurred in connection with the P1 Energy transaction, consulting fees were $31,000 and insurance premiums were $25,000. The recovery of P1 Energy transaction costs in the second quarter of 2011 partially offset these expenses.

The $9,000 foreign exchange gain in 2012 exceeded the $700 foreign exchange gain in 2011.

For the six months ended June 30, 2012, we recorded a net loss of $109,000 or $0.006 per common share based on the weighted average outstanding shares of 19,659,726 during the three month period, compared to a net loss of $155,000 or $0.008 per common share for the quarter ended June 30, 2011 based on the weighted average outstanding shares of 19,659,726. The elimination of research and development expenses of $26,000 from the first half of 2011 to the first half of 2012 is the main reason for the reduced loss in 2012.

Research and development expenses totaled $NIL in the six months ended June 30, 2012, compared to $26,000 in the first half of 2011. Consulting fees were $12,000 and patent fees were $13,000. These costs were incurred in connection with the termination of the Duke License Agreement.

General and administrative expenses were $109,000 in the six months ended June 30, 2012 compared to $122,000 in the same period of the prior year. Major expenses in 2012 consisted of consulting fees of $37,000, insurance premiums of $29,000, transfer agent and stock exchange listing fees of $15,000 and audit fees of $14,000. In 2011, legal fees amounted to $184,000, of which $157,000 was incurred in connection with the P1 Energy transaction, consulting fees were $87,000 and insurance premiums were $36,000. The recovery of P1 Energy transaction costs partially offset these expenses.

Our operational activities for the quarter ended June 30, 2012 were financed by cash on hand. At June 30, 2012, we had working capital of $1,057,000, as compared to $1,165,000 at December 31, 2011. We had available cash of $1,066,000 at June 30, 2012, compared to cash of $1,192,000 at December 31, 2011. The decrease was due to the $109,000 operating loss incurred in the period.

As at July 30, 2012, we have 19,659,726 common shares and options to purchase 1,955,000 common shares outstanding.

Additional information about Bradmer, including the MD&A and financial results may be found on SEDAR at www.sedar.com.

Bradmer's common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.

Except for historical information, this news release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

BRADMER PHARMACEUTICALS INC.
Condensed Interim Statements of Financial Position
As at
(All amounts expressed in United States dollars)
		June 30,			December 31,
		2012			2011
Assets
Current assets
	Cash	$	1,066,086		$	1,192,307
	Amounts receivable		5,114			2,951
	Prepaid expenses		7,405			7,553
Total assets		$	1,078,606		$	1,202,811
Liabilities and Shareholders' Equity
Current liabilities
	Accounts payable and accrued expenses	$	21,950		$	37,451
Shareholders' Equity
	Share capital		2,255,380			2,257,819
	Warrants		-			23,255
	Contributed surplus		2,492,264			2,471,705
	Accumulated other comprehensive loss		(70,588	)		(75,798	)
	Deficit		(3,620,400	)		(3,511,621	)
Total shareholders' equity			1,056,656			1,165,360
Total liabilities and shareholders' equity		$	1,078,606		$	1,202,811

BRADMER PHARMACEUTICALS INC.
Condensed Interim Statements of Comprehensive Loss
For the six months ended June 30, 2012 and 2011
(All amounts expressed in United States dollars)
		Six Months Ended						Three Months Ended
		June 30						June 30
		2012			2011			2012			2011
Expenses
	Research and development	$	-		$	25,899		$	-		$	7,055
	General and administrative expense/(recovery)		109,260			122,315			47,013			(43,531	)
			109,260			148,214			47,013			(36,476	)
Other Income
	Interest		(200	)		(340	)		(108	)		(138	)
	Foreign exchange (gain)/loss		(281	)		7,336			(8,902	)		(726	)
			(481	)		6,996			(9,010	)		(864	)
Net loss/(income) for the period		$	108,779		$	155,210		$	38,003		$	(37,340	)
Other comprehensive loss/(income)			(5,210	)		90,283			(75,589	)		15,484
Comprehensive loss/(income) for the period		$	103,569		$	245,493		$	(37,586	)	$	(21,856	)
Net loss/(income) per share
Basic and diluted		$	0.006		$	0.008		$	0.002		$	(0.002	)
Weighted average number of shares outstanding			19,659,726			19,659,726			19,659,726			19,659,726

BRADMER PHARMACEUTICALS INC.
Condensed Interim Statements of Changes in Shareholders' Equity
For the six months ended June 30, 2012 and 2011
(All amounts expressed in United States dollars)
											Accumulated
	Share capital										Other						Total
	Number of							Contributed			Comprehensive						shareholders'
	shares	Amount			Warrants			surplus			Loss			Deficit			equity
Balance, January 1, 2011	19,659,726	$	2,319,164		$	877,233		$	1,664,319		$	(173,316	)	$	(3,196,658	)	$	1,490,742
Expiry of warrants	-		-			(783,988	)		783,988			-			-			-
Foreign currency translation adjustment	-		61,553			(60,503	)		127,959			(90,284	)		-			38,725
Loss for the period	-		-			-			-			-			(155,210	)		(155,210	)
Balance, June 30, 2011	19,659,726	$	2,380,717		$	32,742		$	2,576,266		$	(263,600	)	$	(3,351,868	)	$	1,374,257
Balance, January 1, 2012	19,659,726	$	2,257,819		$	23,255		$	2,471,705		$	(75,798	)	$	(3,511,621	)	$	1,165,360
Expiry of warrants	-		-			(23,255	)		23,255			-			-			-
Foreign currency translation adjustment	-		(2,439	)		-			(2,696	)		5,210			-			75
Loss for the period	-		-			-			-			-			(108,779	)		(108,779	)
Balance, June 30, 2012	19,659,726	$	2,255,380		$	-		$	2,492,264		$	(70,588	)	$	(3,620,400	)	$	1,056,656

BRADMER PHARMACEUTICALS INC.
Condensed Interim Statements of Cash Flows
For the six months ended June 30, 2012 and 2011
(All amounts expressed in United States dollars)
			2012			2011
Cash flows from operating activities
	Loss for the period		$	(108,779	)	$	(155,210	)
	Adjustments for:
		Foreign exchange loss		75			38,725
				(108,704	)		(116,485	)
	Change in non-cash operating items
		Amounts receivable		(2,163	)		(235,821	)
		Prepaid expenses		148			7,530
		Accounts payable and accrued expenses		(15,502	)		140,129
Decrease in cash				(126,221	)		(204,647	)
Cash at beginning of period				1,192,307			1,524,972
Cash at end of period			$	1,066,086		$	1,320,325